With CRISPR Therapeutics, ViaCyte is developing immune-evasive stem cell lines from its proprietary CyT49 pluripotent stem cell line.
Source link
With CRISPR Therapeutics, ViaCyte is developing immune-evasive stem cell lines from its proprietary CyT49 pluripotent stem cell line.
Source link